Edition:
United Kingdom

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

17.00CHF
15 Aug 2018
Change (% chg)

CHF-0.20 (-1.16%)
Prev Close
CHF17.20
Open
CHF17.20
Day's High
CHF17.50
Day's Low
CHF16.80
Volume
10,784
Avg. Vol
11,962
52-wk High
CHF74.00
52-wk Low
CHF15.90

Chart for

About

Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone... (more)

Overall

Beta: 0.77
Market Cap(Mil.): CHF237.58
Shares Outstanding(Mil.): 6.29
Dividend: --
Yield (%): --

Financials

  SANN.S Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -6.40 -- --
ROI: -37.59 15.07 14.61
ROE: -55.62 16.59 16.33

Swiss stocks - Factors to watch on June 22

ZURICH, June 22 The Swiss blue-chip SMI was seen opening 0.2 percent higher at 8473 points on Friday, according to premarket indications by bank Julius Baer .

22 Jun 2018

BRIEF-Santhera: MHRA Renews Early Access Option For Raxone For Duchenne

* UK'S MHRA RENEWS EARLY ACCESS TO MEDICINES SCHEME SCIENTIFIC OPINION FOR SANTHERA'S RAXONE® (IDEBENONE) IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

22 Jun 2018

BRIEF-Santhera Submits NDA In South Korea For Raxone For The Treatment Of LHON

* SANTHERA SUBMITS NDA IN SOUTH KOREA FOR RAXONE® FOR THE TREATMENT OF LHON

12 Jun 2018

BRIEF-Santhera Successfully Completes First Clinical Trial With Omigapil In Patients With Congenital Muscular Dystrophy ‍​

* SUCCESSFUL COMPLETION OF FIRST CLINICAL TRIAL WITH OMIGAPIL IN PATIENTS WITH CONGENITAL MUSCULAR DYSTROPHY ‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

05 Apr 2018

Swiss stocks - Factors to watch on March 20

ZURICH, March 20 The Swiss blue-chip SMI was seen opening 0.3 percent higher at 8,841 points on Tuesday, according to premarket indications by bank Julius Baer .

20 Mar 2018

BRIEF-Santhera Pharmaceuticals FY ‍Net Result At CHF -51.5 Mln

* SANTHERA PHARMACEUTICALS - FY ‍NET REVENUES FROM SALES OF LEAD PRODUCT RAXONE® INCREASED BY 21% TO CHF 22.9 MILLION​

20 Mar 2018

Santhera's Raxone shows no efficacy benefit in MS study

ZURICH Santhera Pharmaceuticals said on Monday a study of its medicine Raxone in primary progressive multiple sclerosis showed no difference between the treatment and placebo groups in disease progression, another setback for the Swiss drug company.

05 Mar 2018

BRIEF-Santhera Pharmaceuticals ‍Reports Outcome Of Exploratory Trial With Idebenone In PPMS Conducted At NIH​

* ‍REPORTS OUTCOME OF EXPLORATORY TRIAL WITH IDEBENONE IN PPMS CONDUCTED AT NIH​

05 Mar 2018

BRIEF-Santhera Completes Capital Increase To Settle Obtained License From Polyphor

* SANTHERA COMPLETES CAPITAL INCREASE TO SETTLE OBTAINED LICENSE FROM POLYPHOR

22 Feb 2018

Earnings vs. Estimates